ArticleCureus2020
Fatal Rhabdomyolysis in a COVID-19 Patient on Rosuvastatin.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature.Frontiers in medicine · 2024Review
- Article
- Muscle pain and muscle weakness in COVID19 patients: Cross-talk with statins - Preliminary results.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Diagnostic role of technitium-99m bone scan in severe COVID-19-associated myositis.Radiology case reports · 2021Article
- A Case of Fatal Catatonia in a COVID-19 Patient.Cureus · 2021Article
- [Neuromuscular complications of SARS-CoV-2 infection-Part 2: muscle disorders].Der Nervenarzt · 2021Review
- COVID-19: Direct and Indirect Mechanisms of Statins.International journal of molecular sciences · 2021Review
- Neuromuscular disease: 2021 update.Free neuropathology · 2021Article
- Extrapulmonary onset manifestations of COVID-19.Clinics (Sao Paulo, Brazil) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well-established by now that COVID-19 can have a wide variety of neuromuscular manifestations, including rhabdomyolysis. Weakness and elevated creatinine kinase (CK) have been documented as the initial presentation of COVID-19. Myopathy from statin use has also been well-established since the introduction of this class of medication, and the common pathologic mechanism of both entities may have been mitochondrial dysfunction. We present here the case of a COVID-19 patient on rosuvastatin who developed rhabdomyolysis with CK above 1,000,000 units/L. The patient did not present with any respiratory difficulty and responded poorly to treatment, resulting in his untimely demise. COVID-19 may have accentuated an otherwise survivable condition by means of extra stress on mitochondrial homeostasis. Understanding the actual mechanism will be important in the development and utilization of medications in the fight against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.